Literature DB >> 16962860

Does the metabolic syndrome help to select patients requiring high statin dose?

A J Scheen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962860     DOI: 10.1016/S0140-6736(06)69293-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Cannabinoid type 1 receptor mediates depot-specific effects on differentiation, inflammation and oxidative metabolism in inguinal and epididymal white adipocytes.

Authors:  I V Wagner; N Perwitz; M Drenckhan; H Lehnert; J Klein
Journal:  Nutr Diabetes       Date:  2011-09-05       Impact factor: 5.097

2.  Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.

Authors:  Prakash Deedwania; Sabina A Murphy; Andre Scheen; Jolita Badariene; Armando Lira Pineda; Narimon Honarpour; Anthony C Keech; Peter S Sever; Terje R Pedersen; Marc S Sabatine; Robert P Giugliano
Journal:  JAMA Cardiol       Date:  2021-02-01       Impact factor: 30.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.